Shyama Computronics and Servic is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (1) | (0) | (0) | 0 |
| margin % | (79.3) | (556.0) | (23.7) | (4.3) | 18.8 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.04 | 0.10 | 0.11 | 0.00 | 0.11 |
| ROE % · ROCE % | 0.4 · 0.5 | 1.0 · 1.5 | 1.1 · 1.3 | 1.4 · 1.7 | 1.1 · 1.5 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | (2) | 0 | (0) | (0) |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.02 | 0.02 | 0.00 | 0.02 | 0.05 | 0.04 | 0.02 | 0.01 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Newspaper publication notice for 29th AGM | compliance | minimal | — | — |
| 1 Sept 2026 · Annual Report for FY 2025-26 submitted to BSE | compliance | minimal | — | — |
| 1 Sept 2026 · Notice of 29th AGM on 23 Sep 2026 via VC; appoints Whole-time Director and CFO | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Newspaper publication of Q1 FY27 and FY26 financial results | compliance | minimal | — | — |
| 10 Aug 2026 · CFO Swaraj Kumar Singh resigns; Roshni Poddar appointed as new WTD and CFO | management changes | high | — | — |
| 10 Aug 2026 · New CFO appointed; old CFO resigns at Shyama Computronics | management changes | high | — | — |
| 10 Aug 2026 · WTD and CFO resigns; new CFO appointed; Q1 results approved | management changes | high | — | — |
| 10 Aug 2026 · CFO resigns, new CFO appointed; Q1 FY27 results approved | management changes | high | — | — |
| 10 Aug 2026 · Q1 FY27 results; CFO swap with new WTD-CFO appointment | management changes | critical | — | — |
| 10 Aug 2026 · Q1 results approved; CFO resigns, new CFO appointed | management changes | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 31.3 | 28.9 | 89 of 169 | 48% |
| P/B | 0.4 | 3.3 | 4 of 163 | 98% |
| ROCE | 1.5 | 10.8 | 144 of 183 | 21% |
| ROE | 1.1 | 10.4 | 141 of 171 | 18% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 11.2 | 17.5 | 116 of 165 | 30% |
| Revenue growth | 8.7 | 16.3 | 99 of 161 | 39% |
| Profit growth | (49.2) | 30.9 | 133 of 158 | 16% |
| Market cap | 4 | 839 | 182 of 182 | 0% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
